↓ Skip to main content

When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children

Overview of attention for article published in Frontiers in Pharmacology, March 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter
11 X users

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
124 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children
Published in
Frontiers in Pharmacology, March 2018
DOI 10.3389/fphar.2018.00148
Pubmed ID
Authors

Frédérique Rodieux, Laszlo Vutskits, Klara M. Posfay-Barbe, Walid Habre, Valérie Piguet, Jules A. Desmeules, Caroline F. Samer

Abstract

Children represent a vulnerable population in which management of nociceptive pain is complex. Drug responses in children differ from adults due to age-related differences. Moreover, therapeutic choices are limited by the lack of indication for a number of analgesic drugs due to the challenge of conducting clinical trials in children. Furthermore the assessment of efficacy as well as tolerance may be complicated by children's inability to communicate properly. According to the World Health Organization, weak opioids such as tramadol and codeine, may be used in addition to paracetamol and ibuprofen for moderate nociceptive pain in both children and adults. However, codeine prescription has been restricted for the last 5 years in children because of the risk of fatal overdoses linked to the variable activity of cytochrome P450 (CYP) 2D6 which bioactivates codeine. Even though tramadol has been considered a safe alternative to codeine, it is well established that tramadol pharmacodynamic opioid effects, efficacy and safety, are also largely influenced by CYP2D6 activity. For this reason, the US Food and Drug Administration recently released a boxed warning regarding the use of tramadol in children. To provide safe and effective tramadol prescription in children, a personalized approach, with dose adaptation according to CYP2D6 activity, would certainly be the safest method. We therefore recommend this approach in children requiring chronic or recurrent nociceptive pain treatment with tramadol. In case of acute inpatients nociceptive pain management, prescribing tramadol at the minimal effective dose, in a child appropriate dosage form and after clear instructions are given to the parents, remains reasonable based on current data. In all other situations, morphine should be preferred for moderate to severe nociceptive pain conditions.

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 124 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 15%
Student > Postgraduate 11 9%
Other 10 8%
Student > Bachelor 9 7%
Lecturer 7 6%
Other 29 23%
Unknown 39 31%
Readers by discipline Count As %
Medicine and Dentistry 44 35%
Pharmacology, Toxicology and Pharmaceutical Science 12 10%
Nursing and Health Professions 5 4%
Psychology 3 2%
Agricultural and Biological Sciences 2 2%
Other 11 9%
Unknown 47 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2023.
All research outputs
#5,023,965
of 24,088,270 outputs
Outputs from Frontiers in Pharmacology
#2,299
of 17,931 outputs
Outputs of similar age
#93,760
of 335,523 outputs
Outputs of similar age from Frontiers in Pharmacology
#60
of 362 outputs
Altmetric has tracked 24,088,270 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,931 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,523 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 362 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.